Differential effects of Qingre Lishi formula on serum total bile acid and liver function markers in early- and late-onset intrahepatic cholestasis of pregnancy

Dan Xue, Li Hao

Abstract

This study aimed to explore the differential intervention effect of Qingre Lishi formula on serum total bile acid and liver function markers in patients with early-onset and late-onset intrahepatic cholestasis of pregnancy (ICP), and to provide a basis for clinical classification and treatment. The clinical data of patients with ICP were retrospectively analyzed. Patients were divided into early-onset (before 28 weeks of gestation) and late-onset (after 28 weeks of gestation) groups. Both groups received Qingre Lishi formula combined with Western medicine treatment, and the changes in serum biochemical and liver function indicators before and after treatment were compared. Baseline total bile acid levels were significantly higher in the early-onset group than in the late-onset group, while no significant between-group differences were observed in alanine aminotransferase or aspartate aminotransferase levels. After intervention, the decrease in total bile acid levels was more pronounced in the early-onset group, and the between-group difference narrowed after treatment. Liver enzyme levels in both groups were significantly lower than those before treatment. Qingre Lishi formula has a more significant effect on serum total bile acid in patients with early-onset ICP, and can effectively narrow the differences in bile acid metabolism between early-onset and late-onset ICP patients.

Full Text:

PDF

References

Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study, Hepatology, 2014;59(4):1482-91. https://doi.org/10.1002/hep.26617

Wan S, Huang Y, Yang H. Shedding light on the function of autophagy in complicated pregnancies, Cell Death Dis 2026;17(1):182. https://doi.org/10.1038/s41419-025-08311-7

Sarker MR, Canfield D, Ferrara L, Debolt CA. Earlier diagnosis of intrahepatic cholestasis of pregnancy and adverse pregnancy outcomes, Pregnancy (Hoboken), 2025;1(4):e70073. https://doi.org/10.1002/pmf2.70073

Vallejo M, Briz O, Serrano MA, Monte MJ, Marin JJG. Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy, J Hepatol, 2006;44(6):1150-7. https://doi.org/10.1016/j.jhep.2005.09.017

Misra D, Singh N, Faruqi M, Tiwari V, Kumar V, Zafar F. Evaluating the Utility of Liver Transaminases as Predictors of Feto-Maternal Outcome in Lieu of Serum Bile Acids in Intrahepatic Cholestasis of Pregnancy: A Prospective Observational Study, J Obstet Gynaecol India, 2024;74(2):113-8. https://doi.org/10.1007/s13224-023-01881-6

Mathur D, Morgan M, McKenzie J, Wakefield D, Janicki MB, Figueroa R. Intrahepatic cholestasis of pregnancy: dilemma in diagnosis and management, J Matern Fetal Neonatal Med, 2022;35(25):8975-81. https://doi.org/10.1080/14767058.2021.2008896

Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, Kohari K, Bacq Y, Bozkurt N, Brun-Furrer R, Bull L, Estiú MC, Grymowicz M, Gunaydin B, Hague WM, Haslinger C, Hu Y, Kawakita T, Kebapcilar AG, Kebapcilar L, Kondrackienė JR, Koster MPH, Kowalska-Kańka A, Kupčinskas L, Lee RH, Locatelli A, Macias RIR, Marschall HU, Oudijk MA, Raz Y, Rimon E, Shan D, Shao Y, Tribe R, Tripodi V, Yayla Abide C, Yenidede I, Thornton JG, Chappell LC, Williamson C. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses, Lancet, 2019;393(10174):899-909. https://doi.org/10.1016/S0140-6736(18)31877-4

Zhang Y, Lu L, Victor DW, Xin Y, Xuan S. Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis, Hepat Mon, 2016;16(8):e38558. https://doi.org/10.5812/hepatmon.38558

Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy, Cochrane Database Syst Rev, 2020;7(7):CD000493. https://doi.org/10.1002/14651858.CD000493.pub3

Nicastri PL, Diaferia A, Tartagni M, Loizzi P, Fanelli M. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy, Br J Obstet Gynaecol, 1998;105(11):1205-7. https://doi.org/10.1111/j.1471-0528.1998.tb09976.x

Hsueh TP, Lin WL, Dalley JW, Tsai TH. The Pharmacological Effects and Pharmacokinetics of Active Compounds of Artemisia capillaris, Biomedicines, 2021;9(10):1412. https://doi.org/10.3390/biomedicines9101412

Yi YX, Ding Y, Zhang Y, Ma NH, Shi F, Kang P, Cai ZZ, Zhang T. Yinchenhao Decoction Ameliorates Alpha-Naphthylisothiocyanate Induced Intrahepatic Cholestasis in Rats by Regulating Phase II Metabolic Enzymes and Transporters, Front Pharmacol, 2018;9:510. https://doi.org/10.3389/fphar.2018.00510

Wang R, Cheng N, Peng R, Yu Z, Nan M, Cao H. Oral herbal medicine for women with intrahepatic cholestasis in pregnancy: a systematic review of randomized controlled trials, BMC Complement Med Ther, 2020;20(1):303. https://doi.org/10.1186/s12906-020-03097-x

Obstetrics Subgroup CSOO. Guidelines for diagnosis and treatment of intrahepatic cholestasis of pregnancy (2015), Zhonghua Fu Chan Ke Za Zhi, 2015;50(7):481-485.

Heitkemper T, Hofmann T, Phan NQ, Ständer S. Aquagenic pruritus: associated diseases and clinical pruritus characteristics, J Dtsch Dermatol Ges, 2010;8(10):797-804. https://doi.org/10.1111/j.1610-0387.2010.07463.x

Livingston CJ, Freeman RJ, Mohammad A, Costales VC, Titus TM, Harvey BJ, Sherin KM, Choosing WTF. Choosing Wisely®in Preventive Medicine: The American College of Preventive Medicine's Top 5 List of Recommendations, Am J Prev Med, 2016;51(1):141-9. https://doi.org/10.1016/j.amepre.2016.03.009

Chen Z, Liu J. Interpretation of the Experts' Consensus on the criteria for the diagnosis and grading of neonatal asphyxia in China, Transl Pediatr, 2013;2(2):59-63. https://doi.org/10.3978/j.issn.2224-4336.2013.04.02

Winiyom P, Janyoungsak P, Narkwichean A, Khuancharee K, Laosooksathit W. A cost-effectiveness analysis of using umbilical cord blood pH for the diagnosis and management of neonatal asphyxia in term high-risk pregnancy, Int J Gynaecol Obstet, 2024;167(1):281-6. https://doi.org/10.1002/ijgo.15540

Ayres-de-Campos D, Spong CY, Chandraharan E, FIGO IFME. FIGO consensus guidelines on intrapartum fetal monitoring: Cardiotocography, Int J Gynaecol Obstet, 2015;131(1):13-24. https://doi.org/10.1016/j.ijgo.2015.06.020

Spampinato S, Tanderup K, Barcellini A, Burchardt E, Eminowicz G, Šegedin B, Stankiewicz M, Valgma M, Kirchheiner K. Impact of the Common Terminology Criteria for Adverse Events (CTCAE) evolution on toxicity scoring in gynaecological radiotherapy, Radiother Oncol, 2025;207:110881. https://doi.org/10.1016/j.radonc.2025.110881

Dixon PH, Wadsworth CA, Chambers J, Donnelly J, Cooley S, Buckley R, Mannino R, Jarvis S, Syngelaki A, Geenes V, Paul P, Sothinathan M, Kubitz R, Lammert F, Tribe RM, Ch'Ng CL, Marschall HU, Glantz A, Khan SA, Nicolaides K, Whittaker J, Geary M, Williamson C. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy, Am J Gastroenterol, 2014;109(1):76-84. https://doi.org/10.1038/ajg.2013.406

Refbacks

  • There are currently no refbacks.